Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 152   

Articles published

BMY 61.30 +0.51 (0.84%)
price chart
Analyst Update: OvaScience Inc, Bristol-Myers Squibb Co, and Cepheid
Analysts are weighing in today on fertility concern OvaScience Inc (NASDAQ:OVAS), pharmaceutical firm Bristol-Myers Squibb Co (NYSE:BMY), and molecular diagnostics company Cepheid (NASDAQ:CPHD). Here's a quick look at today's brokerage notes ...
Company Update: Bristol-Myers Squibb Co (NYSE:BMY)
[Business Wire] Bristol-Myers Squibb Co (NYSE:BMY) will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015.
Market Update: Bristol-Myers Squibb Company (NYSE:BMY) - Bristol-Myers ...  Jutia Group
Related articles »  
Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb ...
Shares of the company traded at a PE ratio of 33.67. Bristol-Myers Squibb Co.'s shares have fallen by 3.33% in the previous three trading sessions, while the stock has gained 12.79% in the last three months and 8.54% on YTD basis.
Related articles »  
Bristol-Myers Squibb Receives Consensus Recommendation of "Hold" from ...
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 0.84% during mid-day trading on Tuesday, hitting $61.30. 10,975,053 shares of the company's stock traded hands. Bristol-Myers Squibb has a 52-week low of $46.30 and a 52-week high of $61.64.
Fitch Raises Outlook on Bristol-Myers Squibb (BMY) to Stable; Notes Firm ...
Fitch Ratings has affirmed Bristol-Myers Squibb Co.'s (Bristol- Myers, Bristol) (NYSE: BMY) Issuer Default Rating (IDR) at 'A-' and has revised the Rating Outlook to Stable from Negative.
Related articles »  
Bristol-Myers Squibb Co's Hep C Drug Denied; Gilead Sciences Inc. Smiling (for ...
"Best-case scenario, the decision was because the FDA gave Bristol-Myers Squibb (NYSE: BMY ) an indication that the data from clinical trials testing Daklinza combined with Sovaldi -- curing up to 100% of patients in some trials -- will be on Daklinza ...
Related articles »  
Fitch Revises Bristol-Myers Squibb's Outlook to Stable; Affirms IDR at 'A-'
CHICAGO--(BUSINESS WIRE)--Fitch Ratings has affirmed Bristol-Myers Squibb Co.'s (Bristol- Myers, Bristol) Issuer Default Rating (IDR) at 'A-' and has revised the Rating Outlook to Stable from Negative.
Related articles »  
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 05 Filed by: ANDREOTTI ...
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. ANDREOTTI LAMBERTO. (Last), (First), (Middle). BRISTOL-MYERS SQUIBB COMPANY.
Related articles »  
Bristol-Myers Squibb Company : Ono Pharmaceutical, Bristol-Myers Squibb and ...
TOKYO & OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company(NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,"Kyowa Hakko Kirin") announced today the companies have ...
Related articles »  
Bristol-Myers Squibb, Merck & Co Drugs Show Promise In Early Trials For ...
Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc.'s (NYSE:MRK) respective cancer immunotherapies, Opdivo and Keytruda, showed promising results for the treatment of Hodgkin's lymphoma in two separate studies, researchers announced ...
Bristol-Myers, Merck Drugs Give Hope in Hodgkin's Trials  Bloomberg
Two Cancer Drugs for Hodgkin Lymphoma Shown Effective  Wall Street Journal
Related articles »